NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Krispy Kreme, Inc. (NASDAQ: DNUT) between February 25, 2025 and May 7, 2025. Krispy Kreme produces doughnuts. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Krispy Kreme, Inc. (NASDAQ: DNUT) Misled I.

Alphabet remains deeply undervalued despite recent gains, with a forward PE below 20, way lower than Magnificent 7 peers. Rockstar financials, including a 34% ROIC and $95 billion cash pile, position Google to profitably invest in AI and future growth projects. AI leadership, new product launches, and positive Q2 earnings momentum support continued double-digit growth and strong bullish sentiment.

DURHAM, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the final opportunity to buy a new home at Rollingdale by Toll Brothers , a premier community of new construction townhomes in Durham, North Carolina. Only nine homes remain available for sale in this exclusive community, including move-in ready homes with designer appointed finishes. The Toll Brothers Sales Center is open daily at 2117 Opulent Oaks Lane in Durham.

Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva's single-dose chikungunya vaccine IXCHIQ® by EMA's safety committee (PRAC). The committee initiated its review at the beginning of May following the occurrence of serious side effects mainly in elderly people with several underlying medical conditions.

Tyler Ellegard says Meta Platforms (META) is a buy even as it trades just off all-time highs. He sees the Mag 7 giant's ad revenue as a prime growth driver that will continue to accelerate over the next couple of years.

DANBURY, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced its newest 55+ community, Rivington by Toll Brothers - The Meadows Collection , is coming soon to prestigious Fairfield County in Danbury, Connecticut. This exclusive Toll Brothers neighborhood will offer the final collection of new construction townhomes in the award-winning Rivington by Toll Brothers community. Sales are anticipated to begin in late summer 2025.

CAMDEN, N.J.--(BUSINESS WIRE)-- #AmericanWater--American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., announced today that it has been named on TIME's America's Best Mid-Size Companies 2025 list. The ranking is based on three dimensions: Employee Satisfaction, Revenue Growth and Sustainability Transparency. TIME partnered with market research firm Statista to collect data via employee surveys from U.S. companies, Statista's revenue database, and Statista's ESG Datab.

BIL offers a risk-free, highly liquid yield of 4.5%, making it ideal for conservative investors seeking income and capital protection. Persistent inflation and potential tariff impacts may keep rates higher for longer, supporting BIL's attractive yield relative to inflation. In a downturn, BIL provides capital safety and liquidity, allowing investors to redeploy funds into equities at opportune moments.

Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-class potential in CML, with encouraging molecular response and safety data versus Novartis' Scemblix. TERN-601's oral GLP-1 candidate demonstrated promising weight loss and tolerability, targeting a massive obesity market with room for differentiated entrants.

JLL stock gains momentum as outsourcing trends, business resilience and strategic growth boost investor confidence.

Silver prices surged to a nearly 14-year high on Friday as mounting geopolitical tensions and renewed safe-haven demand lifted the precious metal, offsetting pressure from a stronger dollar and mixed trading volumes. Spot silver (XAG/USD) climbed 1.31% to $37.52 per troy ounce, its highest level since 2011, according to FXStreet data.

T-Mobile told the FCC this week that it was ending its DEI policies. The company has been awaiting FCC approval for two deals.

TKO Group's UFC-WWE combo drives robust financials, with double-digit EPS growth, high free cash flow conversion, and expanding margins fueling long-term upside. Despite a premium valuation, my fair value model shows TKO trades at a discount, supported by conservative growth assumptions and strong operational execution. Risks include integration challenges, media rights negotiations, macro headwinds, and live event unpredictability, but TKO's resilient model mitigates these concerns.

The iShares TIPS Bond ETF is set to face an interesting period amid a recalibration in real and nominal yields. The ETF, which has an expense ratio of 0.18% and a 30-day SEC yield of 5.14%, invests in inflation-linked treasuries. We anticipate real yields to settle lower in the next six months. However, we think inflation and breakevens will fall in tandem, softening TIP ETF's return outlook.

Markel Group is set to grow on rate increases, strategic buyouts, new business volume, solid capital position and prudent capital deployment.

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

Ford recalls over 850K vehicles in its 89th action this year, citing fuel pump issues that may cause engine stalls.

HOOD's crypto push and rapid growth clash with SCHW's scale and stability? Let's find out which brokerage stock may lead the next wave of finance.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Iovance Biothera.

Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). In a Complete Response Letter to Capricor, the FDA stated that the application did not meet the statutory requirement for substantial evidence of effectiveness and requested additional clinical data before reconsidering approval.